BR112012008237A2 - produção de uma imunorresposta para a redução do risco de desenvolvimento de brucelose. - Google Patents

produção de uma imunorresposta para a redução do risco de desenvolvimento de brucelose. Download PDF

Info

Publication number
BR112012008237A2
BR112012008237A2 BR112012008237-0A BR112012008237A BR112012008237A2 BR 112012008237 A2 BR112012008237 A2 BR 112012008237A2 BR 112012008237 A BR112012008237 A BR 112012008237A BR 112012008237 A2 BR112012008237 A2 BR 112012008237A2
Authority
BR
Brazil
Prior art keywords
polypeptide
nucleic acid
leub
brucellosis
dna
Prior art date
Application number
BR112012008237-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Gerhardt G. Schurig
Stephen M. Boyle
Nammalwar Srirangnanathan
Original Assignee
Veterinary Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veterinary Technologies Corporation filed Critical Veterinary Technologies Corporation
Publication of BR112012008237A2 publication Critical patent/BR112012008237A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012008237-0A 2009-10-21 2010-04-06 produção de uma imunorresposta para a redução do risco de desenvolvimento de brucelose. BR112012008237A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/589,299 2009-10-21
US12/589,299 US20100226942A1 (en) 2008-10-30 2009-10-21 Producing an immune response for reducing the risk of developing brucellosis
PCT/US2010/001040 WO2011049590A1 (en) 2009-10-21 2010-04-06 Producing an immune response for reducing the risk of developing brucellosis

Publications (1)

Publication Number Publication Date
BR112012008237A2 true BR112012008237A2 (pt) 2020-08-18

Family

ID=42678459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008237-0A BR112012008237A2 (pt) 2009-10-21 2010-04-06 produção de uma imunorresposta para a redução do risco de desenvolvimento de brucelose.

Country Status (6)

Country Link
US (2) US20100226942A1 (es)
EP (1) EP2491142A4 (es)
CN (1) CN102597262A (es)
BR (1) BR112012008237A2 (es)
MX (1) MX2012002829A (es)
WO (1) WO2011049590A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372187B8 (es) * 2009-12-03 2013-04-29 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de identificación de animales vacunados frente a brucella.
WO2014036438A2 (en) * 2012-08-30 2014-03-06 Montana State University Live brucellosis vaccines comprising attenuated brucella mutants
CN112980761A (zh) * 2014-07-10 2021-06-18 国家医疗保健研究所 用于针对布鲁氏菌病的改进疫苗的改性细菌
CN106854654B (zh) * 2017-02-16 2020-06-23 内蒙古医科大学 表达羊种布氏菌L7/L12基因的rBCG及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044431A1 (en) * 1998-06-19 2003-03-06 Gerhardt Schurig Over-expressing homologous antigen vaccine and a method of making the same
AU2003300858A1 (en) * 2002-12-12 2004-07-09 Walter Reed Army Institute Of Research Department Of The Army Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis

Also Published As

Publication number Publication date
US20100226942A1 (en) 2010-09-09
US20120202270A1 (en) 2012-08-09
EP2491142A4 (en) 2013-09-04
WO2011049590A1 (en) 2011-04-28
CN102597262A (zh) 2012-07-18
MX2012002829A (es) 2012-12-17
EP2491142A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
US10842858B2 (en) Compositions and methods of enhancing immune responses to Eimeria
EP3041939B1 (en) Recombinant marek's disease viruses and uses thereof
US7211264B2 (en) Attenuated microorganisms for the treatment of infection
US20040009191A1 (en) Salmonella vaccine materials and methods
EP2214840A1 (en) Compositions and methods of enhancing immune responses to flagellated bacterium
US8337831B2 (en) Live, oral vaccine for protection against Shigella dysenteriae serotype 1
US20190136209A1 (en) Duck enteritis virus and the uses thereof
JP2019524154A (ja) アヒル腸炎ウイルス及びその使用
BR112012008237A2 (pt) produção de uma imunorresposta para a redução do risco de desenvolvimento de brucelose.
JP2001510342A (ja) 新規微生物
JP3372952B2 (ja) 家禽マイコプラズマ抗原、その遺伝子、その遺伝子を含む組み換えベクター、およびそれを利用したワクチン
US20220062411A1 (en) Recombinant viruses and the uses thereof
DE102011121069A1 (de) Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
EP2403947B1 (de) Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
JP5257939B2 (ja) 豚丹毒・豚マイコプラズマ肺炎経口投与型多価ワクチン
US20120202271A1 (en) Method producing an immune response for reducing the risk of developing brucellosis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]